IRD
Opus Genetics, Inc.
There isn't enough reported data to score IRD yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
IRD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
IRD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
IRD PE Valuation
IRD has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
IRD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect IRD's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
IRD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.54 | +$0.34 |
| Q2 2026 | -$1.33 | +$0.59 |
| Q1 2026 | -$1.31 | +$0.79 |
| Q4 2025 | -$0.80 | +$1.35 |
| Q3 2025 | -$1.88 | -$0.81 |
| Q2 2025 | -$1.92 | -$1.39 |
| Q1 2025 | -$2.10 | -$1.63 |
| Q4 2024 | -$2.15 | -$1.69 |
IRD is still losing money, but far less than before: $1.54 per share over the past year, against $11.55 at its worst in early 2021.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over IRD on earnings quality, reporting a profit while its opponent remains loss making.
IRD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1M | -63% |
| Q2 2026 | $755K | -74% |
| Q1 2026 | $2.2M | -51% |
| Q4 2025 | $3.9M | -10% |
| Q3 2025 | $3.1M | -20% |
| Q2 2025 | $2.9M | +159% |
| Q1 2025 | $4.4M | +155% |
| Q4 2024 | $4.3M | +154% |
IRD's revenue has slid since its 2022 peak: $1M last quarter, down 63% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1693% | -1423 points |
| Q2 2026 | -2183% | -1874 points |
| Q1 2026 | -666% | -439 points |
| Q4 2025 | -296% | +588 points |
| Q3 2025 | -270% | -63 points |
| Q2 2025 | -309% | +440 points |
| Q1 2025 | -227% | +223 points |
| Q4 2024 | -884% | -563 points |
IRD's operating margin was −1693% last quarter, down 1423 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over IRD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over IRD on profitability, with a higher operating margin.
IRD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$12M | -$1.7M |
| Q1 2026 | -$12.7M | -$3.7M |
| Q4 2025 | -$9.8M | -$2.4M |
| Q3 2025 | -$6.2M | -$1M |
| Q2 2025 | -$10.3M | -$3M |
| Q1 2025 | -$9M | -$3.3M |
| Q4 2024 | -$7.4M | -264% |
| Q3 2024 | -$5.1M | -$2.1M |
IRD has burned cash in almost every quarter: −$41M over the past year, against −$32M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over IRD on cash generation, producing positive trailing cash flow while its opponent burns cash.
IRD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -8.6% | -9.5M shares |
| 1 year | +44% | +31.2M shares |
| 3 years | +386% | +80.9M shares |
| 5 years | +832% | +90.9M shares |
| Available history | +10187% | +101M shares |
IRD has 102M diluted shares, up 44% from a year ago.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over IRD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
IRD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -2.3x | Net Cash |
IRD has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
IRD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.5 | Neutral |
| Stochastic | 20.4 | Neutral |
IRD's weekly RSI is 50 (neutral) and its Stochastic is 20 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
IRD PE vs Healthcare Sector
| Metric | IRD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IRD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IRD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.15 | 2.2% below |
| 20 week MA | $4.12 | 1.5% below |
| 50 week MA | $3.91 | 3.8% above |
| 100 week MA | $2.58 | 57% above |
| 200 week MA | $2.68 | 51% above |
IRD has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
IRD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.08 | $5.49 | -32% |
| 2021 | $5.49 | $3.81 | -31% |
| 2022 | $3.81 | $2.51 | -34% |
| 2023 | $2.51 | $3.01 | +20% |
| 2024 | $3.01 | $1.18 | -61% |
| 2025 | $1.18 | $2.02 | +71% |
| 2026 YTD | $2.02 | $4.06 | +101% |
IRD has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.